ID   IRAK2_RAT               Reviewed;         624 AA.
AC   Q4QQS0;
DT   06-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2005, sequence version 1.
DT   29-MAY-2024, entry version 122.
DE   RecName: Full=Interleukin-1 receptor-associated kinase-like 2;
DE            Short=IRAK-2;
GN   Name=Irak2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Binds to the IL-1 type I receptor following IL-1 engagement,
CC       triggering intracellular signaling cascades leading to transcriptional
CC       up-regulation and mRNA stabilization. {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with MYD88. IL-1 stimulation leads to the formation
CC       of a signaling complex which dissociates from the IL-1 receptor
CC       following the binding of PELI1 (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The protein kinase domain is predicted to be catalytically
CC       inactive.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. Pelle subfamily. {ECO:0000305}.
CC   -!- CAUTION: Asn-335 is present instead of the conserved Asp which is
CC       expected to be an active site residue. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC098060; AAH98060.1; -; mRNA.
DR   RefSeq; NP_001020593.1; NM_001025422.1.
DR   AlphaFoldDB; Q4QQS0; -.
DR   SMR; Q4QQS0; -.
DR   STRING; 10116.ENSRNOP00000034508; -.
DR   iPTMnet; Q4QQS0; -.
DR   PhosphoSitePlus; Q4QQS0; -.
DR   PaxDb; 10116-ENSRNOP00000034508; -.
DR   Ensembl; ENSRNOT00000029819.5; ENSRNOP00000034508.4; ENSRNOG00000021817.6.
DR   Ensembl; ENSRNOT00055013419; ENSRNOP00055010747; ENSRNOG00055007933.
DR   Ensembl; ENSRNOT00060021636; ENSRNOP00060017104; ENSRNOG00060012728.
DR   GeneID; 362418; -.
DR   KEGG; rno:362418; -.
DR   UCSC; RGD:1309584; rat.
DR   AGR; RGD:1309584; -.
DR   CTD; 3656; -.
DR   RGD; 1309584; Irak2.
DR   eggNOG; KOG1187; Eukaryota.
DR   GeneTree; ENSGT00940000159835; -.
DR   HOGENOM; CLU_000288_173_0_1; -.
DR   InParanoid; Q4QQS0; -.
DR   OMA; ALSEWDW; -.
DR   OrthoDB; 2999496at2759; -.
DR   PhylomeDB; Q4QQS0; -.
DR   TreeFam; TF328924; -.
DR   Reactome; R-RNO-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-RNO-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-RNO-9020702; Interleukin-1 signaling.
DR   Reactome; R-RNO-937042; IRAK2 mediated activation of TAK1 complex.
DR   Reactome; R-RNO-937072; TRAF6-mediated induction of TAK1 complex within TLR4 complex.
DR   Reactome; R-RNO-975163; IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation.
DR   PRO; PR:Q4QQS0; -.
DR   Proteomes; UP000002494; Chromosome 4.
DR   Bgee; ENSRNOG00000021817; Expressed in jejunum and 19 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0060090; F:molecular adaptor activity; ISO:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0035591; F:signaling adaptor activity; ISO:RGD.
DR   GO; GO:0007249; P:canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IBA:GO_Central.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0001959; P:regulation of cytokine-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0070555; P:response to interleukin-1; ISO:RGD.
DR   GO; GO:0008063; P:Toll signaling pathway; IBA:GO_Central.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; ISO:RGD.
DR   CDD; cd08795; Death_IRAK2; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR042151; Death_IRAK2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   PANTHER; PTHR24419; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE; 1.
DR   PANTHER; PTHR24419:SF2; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE-LIKE 2; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Nucleotide-binding; Reference proteome.
FT   CHAIN           1..624
FT                   /note="Interleukin-1 receptor-associated kinase-like 2"
FT                   /id="PRO_0000277562"
FT   DOMAIN          13..94
FT                   /note="Death"
FT   DOMAIN          210..475
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          508..536
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          549..593
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         216..224
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         237
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         337..340
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
SQ   SEQUENCE   624 AA;  69237 MW;  EF8995F30AB4FDD5 CRC64;
     MACYIYQLPS WVLDDLCRNI DTLSEWDWMQ FASYVITDLT QLRKIKSMER VQGVSITREL
     LWWWSMRQAT VQQLVDLLCH LELYRAAQIV LSWKPAPDSL SPLSAFPEAV KPGPVATSGR
     NLKDDQKKGQ PVKPCSFLSS GTTMAGAQQQ ASCQRPCEED APCSLKTDVP DSLQSKYCST
     SIPKQEKLLN LPGDRLFWSE ADIVQATEDF DQSHRISEGT FADIYRGQRN GVAFAFKRLR
     EVTGSSPGSM DRFLQAEMQL CLRCCHPNIL PLLGFCTGRQ FHSLIYPYMA NGSLQDRLWA
     QGDSDMLSWP QRASICSGLL LAVEHLHSLD IIHSNVKSAN VLLDQHLNPK LAHPVAHPCP
     TNKKTKYTVM KTHLFQASAA YLPENFIRVG QLTKQVDIFS CGIVLAEVLT GIPAMDKDRS
     PVYLKDLLLS EIPSNTSSVH SRKTSMGKVV VKEICQKHLE RKAGLLPEAC AETWATAVSV
     CLRRREASLE EARVSMAGVE EQLRGQLSLP WSRVSEDTGS SSNTPEETDD VDNSSLSVPS
     SVMVVSCARV SSPPPSMGNG TAQPSTSGRQ EADSSSEACA GPQPPQEATE TSWKIEINEA
     KRRLMENILL YKEEKLDSVE LFGP
//
